Cat. No S57C3D-262261_50_MG
US-CATO

Product Information

Product Name
(R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno3,2-dpyrimidine 5-oxide
Brand Name
US-CATO
Product Number
C3D-262261
CAS
1423719-30-5
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
166177189
IUPAC Name
1-(5R)-2-4-(5-chloropyrimidin-2-yl)piperidin-1-yl-5-oxo-6,7-dihydrothieno3,2-dpyrimidin-4-ylaminocyclobutylmethanol
InChI Key
UHYCLWAANUGUMN-SSEXGKCCSA-N
SMILES
C1CC(C1)(CO)NC2=NC(=NC3=C2S@(=O)CC3)N4CCC(CC4)C5=NC=C(C=N5)Cl

References Data Source From Pubchem

Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast

Publication Name: American Journal of Respiratory Cell and Molecular Biology
Publication Date: 2025-11-01
DOI: 10.1165/rcmb.2024-0614oc

Nerandomilast – A Multifrontal Therapeutic Approach to Lung Fibrosis

Publication Name: American Journal of Respiratory Cell and Molecular Biology
Publication Date: 2025-11-01
DOI: 10.1165/rcmb.2025-0140ed

Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis

Publication Name: Therapeutic Advances in Respiratory Disease
Publication Date: 2025-01
DOI: 10.1177/17534666241309795

Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases

Publication Name: Clinical and Experimental Rheumatology
Publication Date: 2024-01-08
DOI: 10.55563/clinexprheumatol/yg6rck

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

Publication Name: Frontiers in Pharmacology
Publication Date: 2022-04-20
DOI: 10.3389/fphar.2022.838449

(R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide

Just added to your wishlist:
My Wishlist
You've just added this product to the cart:
Go to cart page